Preview
November 2019
In the next issue of Pharma Technology Focus we delve into the complex topic of data manipulation after Novartis was accused of submitting a drug application with manipulated data to the US FDA, find out how pharma is tackling Dengue fever, and ask what can be done to improve the pharma patent system.
Also, we find out about a new method for attaching drugs to antibodies using unsaturated phosphorus compounds, get industry insight into the challenges of developing transplant rejection drugs, and take a look at the need for non-hormonal treatments for menopause with Astellas.
Plus, we round up the ‘wonder drugs’ that have been approved for multiple indications and explore the future of Chlamydia treatment.
EDITORIAL
Editor | Eloise McLennan
Group Editor | Susanne Hauner
Commissioning Editor| Daniel Garrun
Writers | Allie Nawrat, Abi Millar, Chris Lo
Magazine Designer | Marzia Del Gaone
Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Filipe Costa
Lead Designer | John Hammond
Digital Publishing Director | Duncan West
Advertising
Sales Manager | Nimai Amin
+44 (0) 207 936 6453
Marketing
media partnership enquiries: Sophie Hoare: Sophie Hoare
Pharma Technology focus is powered by h5mag
read past issues of pharma technology focus HERE
Pharma Technology Focus is a product of Net Resources International. Copyright 2019 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.